

#67

COMPLETE

Collector: Email Invitation 1 (Email)
Started: Tuesday, April 24, 2018 2:48:59 PM
Last Modified: Tuesday, April 24, 2018 3:07:35 PM
Time Spent: 00:18:35
First Name: [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

Page 2: General Information

Q1 Focal point contact details

Name [REDACTED]
[REDACTED] onal
[REDACTED]; [REDACTED]
[REDACTED]
[REDACTED] e

Q2 Please indicate your country **Germany**

Page 3: WHO Data Sharing Policy

Q3 Please confirm that you agree **I agree for the information provided in this questionnaire to be published in a report**

Page 4: General cannabis information

Q4 Do you have any information about the use of cannabis plant/cannabis resin for any purpose (including medical or non-medical use) in your country? **Yes**

Page 5: Medical use of cannabis plant /resin

Q5 At national level, is cannabis plant or resin legally approved for medical use in your country? **Yes**

Page 6: Medical use: Therapeutic indications

WHO ECDD Questionnaire: Cannabis Plant and Cannabis Resin

Q6 Please indicate any approved therapeutic indications for the use of cannabis plant/resin in your country

Other (please specify):

There are no limitations to specific therapeutic indications but there's the limitation that only severely ill patients can receive medicinal cannabis who according to a doctor's decision can't be treated properly with other medications.

Q7 Please indicate any symptoms that cannabis plant/resin is approved to treat

Other (please specify):

There are no limitations to specific symptoms but there's the limitation that only severely ill patients can receive medicinal cannabis who according to a doctor's decision can't be treated properly with other medications.

Q8 Please indicate whether there are any permitted marketed products of cannabis plant and cannabis resin.

Name of marketed product & CBD /THC content (if known):

See uploaded file: List of Cannabis flowers permitted by BfArM for medical use

Q9 Are there any ongoing approved clinical trials in your country that are developing cannabis plant/resin for medical use?

No

Q10 Please indicate product name/ trial number/ study phase of any ongoing trials that are developing products of cannabis plant/ resin for medical use

Respondent skipped this question

Page 7: Medical use: Access

Q11 Do individuals require a prescription to obtain medical cannabis plant or resin?

Yes

Q12 What types of professionals are allowed to prescribe cannabis plant and cannabis resin?

Medical doctor / psychiatrist

Q13 What kinds of settings are approved to legally dispense cannabis plant/resin in your country?

Pharmacies

Q14 If patients use medical cannabis plant/resin on prescription or recommendation of a health professional, will they be reimbursed for the costs of their medication?

Other (please specify):

Dried Cannabis flowers as a medicine are reimbursed for patients who are severely ill and who have no other alternative in therapies.

WHO ECDD Questionnaire: Cannabis Plant and Cannabis Resin

Q15 Are any clinical guidelines used in your country for the prescribing of medical cannabis plant/resin?

Yes (please specify):

The German Medical Association (Bundesärztekammer) has published a compilation of frequently asked questions relating to the medical prescription of Cannabis (See uploaded file).

Q16 Is there a regulatory agency in your country that monitors cannabis plant/ cannabis resin for medical use?

Yes (please specify):

There is a non interventional companion survey from the Federal Institute for Drugs and Medical Devices (BfArM) to receive more data about the medical use and benefit of Cannabis. Furthermore, all medicinal Cannabis products are subject to the pharmacovigilance system.

Q17 How would you describe the trend in the number of users of cannabis plant/cannabis resin for medical use over the last 3 years?

Cannabis plant
Cannabis resin

The number has substantially increased
Don't know/ unsure

Page 8: Medical use: National legislation

Q18 In the past 3 years, has your country changed its national legislation around access to cannabis-related substances for medical use?

Cannabis plant/ cannabis resin

Yes, my country has changed its legislation

Q19 If yes, what types of legislative changes has your country made for medical use of cannabis plant/ resin?

Change to the legal status of medical cannabis ,

Changes to the supply of medical cannabis (e.g. changes in licensing, import – or export of products) ,

Changes to access to medical cannabis (e.g. variety in products, therapeutic indications etc)

Q20 Is your country currently considering changes to its national legislation around access to cannabis and cannabis-related substances for medical use?

Cannabis plant and cannabis resin

No, my country is not preparing changes in its legislation

WHO ECDD Questionnaire: Cannabis Plant and Cannabis Resin

Q21 In your opinion, how do you feel the changed legislation around access to cannabis plant/resin for medical use would impact / has impacted public health in your country?

Increased availability for medical use

There would be/ has been a slightly positive impact on public health

Decreased availability for medical use

There would be /has been a slightly negative impact on public health

Page 9: Non-medical use of cannabis plant and cannabis resin

Q22 On a national level, is cannabis plant (or cannabis resin) legally available for non-medical use in your country? **No**

Q23 Is cannabis plant/ cannabis resin used for cultural, ceremonial, or religious purposes in your country? **No**

Q24 Does your country collect prevalence data around the use of cannabis plant / cannabis resin? **Yes**

Page 10: Prevalence of non-medical cannabis use

Q25 Prevalence of use of cannabis plant/ resin amongst adults (over 18 years of age)

Number (or % of population) used in lifetime **27,2%**

Number (or % of population) used in the last year **6,1%**

Number (or % of population) used in the past month **3,1%**

Year of survey data **2015**

Q26 Prevalence of use of cannabis plant/ resin for non-medical use amongst young people (below 18 years of age)

Number (or % of population) used in lifetime **9,7%**

Number (or % of population) used in the last year **7,3%**

Number (or % of population) used in the past month **2,2%**

Year of survey data **2015**

Q27 How would you describe the number of users cannabis plant/cannabis resin for non-medical use over the last 3 years in your country?

Non-medical use by adults **There has been a significant increase in use**

Non-medical use by young people (below age 18) **There has been a significant increase in use**

Page 11: Public health impact of use: Primary Care

Q28 Does your country collect data about presentations to primary care settings due to the use of cannabis plant/resin? **No**

Page 12: Primary Care II

Q29 Number of primary care presentations relating to cannabis plant/resin **Respondent skipped this question**

Q30 Does your country collect data about presentations to emergency care settings due to the use of cannabis plant/resin? **No**

Page 13: Public health: Emergency settings

Q31 Number of individuals in the past year presenting to emergency settings relating to the use of cannabis plant/resin **Respondent skipped this question**

Q32 Please list the adverse effects presented for cannabis plant/resin at the emergency room/department **Respondent skipped this question**

Q33 Does your country collect data about presentations to substance misuse treatment settings due to the use of cannabis plant/resin? **Yes**

Page 14: Public health: Substance misuse treatment

WHO ECDD Questionnaire: Cannabis Plant and Cannabis Resin

Q34 Number of individuals in the past year presenting to substance misuse treatment due to cannabis plant/resin

Relating to substance alone

16.440 cases of “substance alone” if you exclude only additional illicit substances (Data refers to all treatment episodes, not individuals (double counting is possible) and to all types of cannabinoids, not just plant / resin. However, the vast majority of those treated is treated for the use of cannabis, so the numbers may be used as an estimate.)

Relating to substance and other substances

17.852 cases with comorbid illicit drug use, excluding alcohol and tobacco diagnoses (Data refers to all treatment episodes, not individuals (double counting is possible) and to all types of cannabinoids, not just plant / resin. However, the vast majority of those treated is treated for the use of cannabis, so the numbers may be used as an estimate.)

Year of data collection

2016

Q35 Does your country collect data about calls to poison centres due to the use of cannabis plant/resin? **No**

Page 15: Public health impact: Poison control centres

Q36 Number of calls to poison control centres due to the use of cannabis plant/ resin **Respondent skipped this question**

Q37 Does your country collect data about cases of impaired driving due to the use of cannabis plant/ resin? **No**

Page 16: Public health impact: Impaired driving

Q38 Number of cases of impaired driving due to cannabis plant/ resin **Respondent skipped this question**

Page 17: Non-Medical Use: National legislation

Q39 In the past 3 years, has your country changed its national legislation around access to cannabis plant/resin for non-medical use?

Cannabis plant/ cannabis resin

No, my country has not changed its legislation

Q40 If yes, what types of legislative changes has your country made for non-medical use of cannabis plant/ resin? **Respondent skipped this question**

WHO ECDD Questionnaire: Cannabis Plant and Cannabis Resin

Q41 Is your country currently considering changes to its national legislation around access to cannabis plant/resin for non-medical use?

Cannabis plant and cannabis resin

No, my country is not preparing changes in its legislation

Q42 In your opinion, how do you feel the changed legislation around access to cannabis plant or cannabis resin for non-medical use would impact / has already impacted public health in your country?

Increased availability for non-medical use

There would be/ has been a significantly negative impact on public health

Decreased availability for non-medical use

There would be/ has been a significantly positive impact on public health

Please explain your response::

See uploaded file: Summary of a scientific analysis concerning the potential and risks of cannabis (CaPRis)

Page 18: Additional comments / information

Q43 Comments

Respondent skipped this question

Q44 File upload

List_of_cannabis_flowers_permitted.docx (19.8KB)

Q45 File upload

Kurzbericht_CAPRis.pdf (190KB)

Q46 File upload

FAQ Cannabis_Bundesärztekammer.pdf (269.5KB)